Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending January 2010. The report discloses a notifiable change in share interest regarding Maxygen, Inc., a U.S.-based biopharmaceutical company focused on protein drug development.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only quantitative data relates to equity holdings:
- Shares Sold: 5,121,488 Common shares of Maxygen, Inc.
- Remaining Holdings: 1,433,361 shares.
- Ownership Percentage: 4.47% of Maxygen's outstanding shares (based on 32,041,239 total shares).
Material Changes
GSK reduced its stake in Maxygen, Inc. on December 30, 2009. This reduction was triggered by a tender offer initiated by Maxygen to repurchase its own shares. The transaction resulted in a decrease in GSK's ownership from a prior undisclosed level to 4.47%.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies beyond the disclosure of the share reduction. The transaction is noted as disclosable under the rules of the United States Securities Exchange Act of 1934.
Investor Verification Points
- Verify the current market price of Maxygen, Inc. shares to assess the financial impact of the 5,121,488 shares sold.
- Confirm the terms of the Maxygen tender offer that necessitated the share repurchase.
- Review GSK's broader portfolio of biopharmaceutical investments to understand the strategic significance of reducing the Maxygen stake to 4.47%.